RSV Human Viral Challenge Studies

RSV Human Viral Challenge Studies

Contract Research

Information

hVIVO is the global leader in conducting human viral challenge studies also recently referred to as Controlled Human Infection Models or CHIM. We have inoculated over 750 subjects in human viral challenge studies for Respiratory Syncytial Virus(RSV) vaccines and treatments. Positive results from an RSV challenge study conducted with hVIVO have led to a large increase in asset valuation and fast track status at the FDA. We will be presenting the data from our RSV pilot challenge study in adults 55-75 years of age on Thursday. More details are available in the link.
hVIVO​hVIVO plc (“hVIVO”), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

Log in